Overview
Biote Q2 2025 revenue misses analyst expectations, per LSEG data
Net income rises to $3.9 mln, driven by dietary supplement sales
Company initiated reorganization to boost clinic and procedure growth
Outlook
Biote revises 2025 revenue guidance to above $190 mln
Company expects 2025 adjusted EBITDA above $50 mln
Biote sees 2025 procedure revenue decreasing at high single-digit rate
Company forecasts 2025 dietary supplement revenue to grow at mid-teens rate
Result Drivers
DIETARY SUPPLEMENT SALES - Increased 30.4% year-over-year, contributing positively to revenue
GROSS MARGIN EXPANSION - Improved to 71.6% due to vertical integration and cost management
REORGANIZATION - Initiated restructuring to enhance productivity and drive long-term success
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | $48.90 mln | $49.50 mln (5 Analysts) |
Q2 EPS | $0.1 | ||
Q2 Adjusted EBITDA | $15.20 mln | ||
Q2 Gross Margin | 71.6% | ||
Q2 Adjusted EBITDA Margin | 31.1% | ||
Q2 Operating Income | $10.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the professional information services peer group is "buy"
Wall Street's median 12-month price target for Biote Corp is $7.00, about 40.4% above its August 5 closing price of $4.17
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nBw4Pl6kya
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。